Skip to main content

Escientia Switzerland becomes Primopus

| News

Escientia Switzerland becomes Primopus


The Indian company Deccan Fine Chemicals is acquiring Escientia Switzerland and renaming it as Primopus AG. The new owner announces investments in the Basel Area production facility. The Swiss subsidiary of America’s Escientia Life Sciences Group was established in the Basel region in 2020.

Primopus, formerly Escientia Switzerland, is based at the Getec Park in Muttenz (img: Getec

Deccan Fine Chemicals Private Ltd has announced the acquisition of Escientia Switzerland AG. In future, it will be called Primopus. Escientia, the Swiss subsidiary of the U.S. company Escientia Life Sciences Group, was established in 2020 with the support of Standortförderung Baselland and the location and innovation promotion agency Basel Area Business & Innovation.

According to a press release, Deccan, one of the world’s largest contract development and manufacturing organizations (CDMO companies), will be investing in a production plant taken over from Novartis spanning 17,000 square meters as part of this acquisition. It is expected to become operational in the second half of 2023.

Supply chain for pharmaceutical industry

According to the information provided, Primopus will focus on providing a hybrid supply chain for the pharmaceutical industry from its location at Getec Park in Muttenz in the canton of Basel-Landschaft. This will be linked to Deccan’s three large fine chemical sites in India. Furthermore, Deccan has announced that Primopus will further develop its research and development capacities.

Marcel Velterop has been named as the CEO. He commented that he is certain that bridging the skills and capabilities of the Swiss operation with the large talent and capacity pool in India will bring unique value and assurance to global players in the pharma supply chain, especially in the current geopolitical environment.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.